NCT05113641Completed
Reducing Dietary Acid With Food Versus Oral Alkali in People With Chronic Kidney Disease (ReDACKD)
Reducing Dietary Acid With Fruit and Vegetables Versus Oral Alkali in People With Chronic Kidney Disease (ReDACKD) Feasibility Trial
Source: ClinicalTrials.gov · Last updated 23 Oct 2026
Brief summary (registry, in English)
Metabolic acidosis is a common problem that occurs with worsening chronic kidney disease. Dietary acid can build up when the kidneys are not working well. This can be associated with a higher risk of worsening kidney function and death. The usual treatment is a medication called sodium bicarbonate which works to balance the acids in the body. The medication however often does not work and causes side effects. Consumption of alkalizing fruit and vegetables may work as a treatment for metabolic acidosis. This trial is being done to see if fruit and vegetables, provided via home delivery, can become a viable management for metabolic acidosis in patients with chronic kidney disease.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 37 (actual)
- First submitted
- 15 Oct 2021
- Start date
- 4 Aug 2023
- Primary completion date
- 24 Sept 2026
- Lead sponsor
- Dylan MacKay
- Diseases
- Chronic kidney disease
- NCT number
- NCT05113641
What you commit to
- Study type: Interventional
- Participants enrolled: 37
- From 4 Aug 2023 to the primary completion date, 24 Sept 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Anuria, dialysis or acute kidney injury/acute kidney failure in the 3 months prior to screening
- Participants who have participated in another research trial involving an investigational product in the past 12 weeks
Other illness
- Chronic obstructive pulmonary disease that requires the participant to be on oxygen
- New York Heart Association Class 3-4 Heart failure symptoms or heart, liver or renal transplant
- A myocardial infarction or stroke within the last 6 months
Lab values
- Currently on potassium binding therapy
Other
- Unable to consume study treatments or control, such as swallowing or GI issues
- Female participant who is pregnant or on lactating
Who the study is looking for
- Participant is willing and able to give informed consent for participation in the trial
- Male or Female, aged 18 years or above
- Participants who have an eGFR between 15 and 40 ml/min/1.73m2
- Two consecutive measurements of serum bicarbonate of 14 to 22 mEq/L
- Systolic and diastolic blood pressure \<160/100 mmHg
- Serum potassium \<5.3 mmol/L
- Hemoglobin A1c below ≤ 11%
- Are registered in the nephrology clinic in Winnipeg or Halifax
- Participants are able to communicate in English and provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chronic Kidney Disease (Renal) ClinicQEII - Dickson Building Coordinator of this site? Confirm its status | Halifax | Canada | Unknown status |
| Seven Oaks General Hospital Chronic Disease Innovation Centre Coordinator of this site? Confirm its status | Winnipeg | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.